Key result
Ablation of CD301b/MGL2+ mononuclear phagocytes, deletion of Syk or VLA-4, or antibody blockade of TNF and IL-6 protected K/B.g7 mice from developing autoimmune mitral valve disease.
CD301b/MGL2+ mononuclear phagocytes and associated inflammatory pathways (Syk, TNF, IL-6, VLA-4) are key drivers of autoimmune mitral valve disease, offering potential therapeutic targets.
May identify targets for autoimmune mitral valve disease; hypothesis-generating in mice, clinical translation remains open.
Background: Valvular heart disease is common and affects the mitral valve (MV) most frequently. Despite the prevalence of MV disease (MVD), the cellular and molecular pathways that initiate and perpetuate it are not well understood. Methods: K/B.g7 T-cell receptor transgenic mice spontaneously develop systemic autoantibody-associated autoimmunity, leading to fully penetrant fibroinflammatory MVD and arthritis. We used multiparameter flow cytometry, intracellular cytokine staining, and immunofluorescent staining to characterize the cells in inflamed K/B.g7 MVs. We used genetic approaches to study the contribution of mononuclear phagocytes (MNPs) to MVD in this model. Specifically, we generated K/B.g7 mice in which either CX3CR1 or CD301b/macrophage galactose N -acetylgalactosamine–specific lectin 2 (MGL2)–expressing MNPs were ablated. Using K/B.g7 mice expressing Cx3Cr1 -Cre, we conditionally deleted critical inflammatory molecules from MNPs, including the Fc-receptor signal-transducing tyrosine kinase Syk and the cell adhesion molecule very late antigen–4. We performed complementary studies using monoclonal antibodies to block key inflammatory molecules. We generated bone marrow chimeric mice to define the origin of the inflammatory cells present in the MV and to determine which valve cells respond to the proinflammatory cytokine tumor necrosis factor (TNF). Finally, we examined specimens from patients with rheumatic heart disease to correlate our findings to human pathology. Results: MNPs comprised the vast majority of MV-infiltrating cells; these MNPs expressed CX3CR1 and CD301b/MGL2. Analogous cells were present in human rheumatic heart disease valves. K/B.g7 mice lacking CX3CR1 or in which CD301b/MGL2-expressing MNPs were ablated were protected from MVD. The valve-infiltrating CD301b/MGL2 + MNPs expressed tissue-reparative molecules including arginase-1 and resistin-like molecule α. These MNPs also expressed the proinflammatory cytokines TNF and interleukin-6, and antibody blockade of these cytokines prevented MVD. Deleting Syk from CX3CR1-expressing MNPs reduced their TNF and interleukin-6 production and also prevented MVD. TNF acted through TNF receptor–1 expressed on valve-resident cells to increase the expression of vascular cell adhesion molecule–1. Conditionally deleting the vascular cell adhesion molecule-1 ligand very late antigen–4 from CX3CR1-expressing MNPs prevented MVD. Conclusions: CD301b/MGL2 + MNPs are key drivers of autoimmune MVD in K/B.g7 mice and are also present in human rheumatic heart disease. We define key inflammatory molecules that drive MVD in this model, including Syk, TNF, interleukin-6, very late antigen–4, and vascular cell adhesion molecule–1.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2018) studied Autoimmune mitral valve disease. Ablation of CD301b/MGL2+ mononuclear phagocytes or blockade of TNF/IL-6 vs. Untreated/unablated K/B.g7 mice was evaluated on Development of mitral valve disease. Ablation of CD301b/MGL2+ mononuclear phagocytes, deletion of Syk or VLA-4, or antibody blockade of TNF and IL-6 protected K/B.g7 mice from developing autoimmune mitral valve disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: